Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and ResultsGlobeNewswire (press release)As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and… Continue reading
Seeking Alpha |
FDA designates Omeros’ OMS721 for accelerated review for stem cell transplant-associated clotting disorder; shares …
Seeking Alpha Omeros (OMER +9.3%) is up on modestly higher volume in response to its announcement that the FDA has designated lead candidate OMS721 a Breakthrough Therapy for the treatment of patients with high-risk hematopoietic stem cell transplant-associated … FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk …Business Wire (press release) |
OncLive |
Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma
OncLive Chimeric antigen receptor (CAR) T-cell therapy has demonstrated potential for patients with relapsed/refractory multiple myeloma, and improvements in efficacy and safety may facilitate its transition into earlier-stage settings, says Maung Myo Htut, MD. What’s the Total Cost of One CAR T-Cell Treatment? – MedscapeMedscape CAR-T 2.0? A split, universal and programmable system …FierceBiotech Analysis determines true cost for CAR T-cell therapy – HealioHealio Endpoints News –Medical Xpress all 8 news articles » |